You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Last Updated: February 24, 2020

DrugPatentWatch Database Preview

ENTYVIO Drug Profile

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Summary for Tradename: ENTYVIO

Patents:	17
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for ENTYVIO

Recent Clinical Trials for ENTYVIO

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
M.D. Anderson Cancer Center	Early Phase 1
National Cancer Institute (NCI)	Early Phase 1
Genentech, Inc.	Phase 2

See all ENTYVIO clinical trials

Pharmacology for ENTYVIO

Mechanism of Action	Integrin Receptor Antagonists

Patent Text Search: US Patents for ENTYVIO

These patents were identified by searching patent claims

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Takeda Pharms Usa	ENTYVIO	vedolizumab	INJECTABLE;INJECTION	125476	001	2014-05-20	Start Trial	MILLENNIUM PHARMACEUTICALS, INC. (Cambridge, MA)	2031-05-02	RX		search
Takeda Pharms Usa	ENTYVIO	vedolizumab	INJECTABLE;INJECTION	125476	001	2014-05-20	Start Trial	Millennium Pharmaceuticals, Inc. (Cambridge, MA)	2031-05-02	RX		search
Takeda Pharms Usa	ENTYVIO	vedolizumab	INJECTABLE;INJECTION	125476	001	2014-05-20	Start Trial	CureVac AG (Tubingen, DE)	2032-02-15	RX		search
Takeda Pharms Usa	ENTYVIO	vedolizumab	INJECTABLE;INJECTION	125476	001	2014-05-20	Start Trial	Millennium Pharmaceuticals, Inc. (Cambridge, MA)	2031-05-02	RX		search
Takeda Pharms Usa	ENTYVIO	vedolizumab	INJECTABLE;INJECTION	125476	001	2014-05-20	Start Trial	INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE PARIS DIDEROT--PARIS 7 (Paris, FR) ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR)	2034-06-24	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patents for ENTYVIO

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Portugal	2704798	Start Trial
China	108079291	Start Trial
Spain	2646717	Start Trial
South Korea	101923378	Start Trial
Mexico	2015011462	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter

Moodys

Express Scripts

Dow

Colorcon

Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.